DA-EPOCH

DRUG3 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, National Cancer Institute (NCI), The Affiliated People's Hospital of Ningbo University

Conditions

DLBCLDiffuse Large B-Cell LymphomaHematopoietic Stem Cell MobilizationNHLNHL With Hemophagocytic LymphohistiocytosisNon-Hodgkin's Lymphoma

Phase 2

Trial of DA-EPOCH Regimen for NHL With HLH

The First Affiliated Hospital with Nanjing Medical UniversityNHL With Hemophagocytic Lymphohistiocytosis

Start: 2012-06-30End: 2019-04-30Target: 50Updated: 2019-02-15

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

RecruitingNCT04002947

National Cancer Institute (NCI)Diffuse Large B-Cell Lymphoma, DLBCL, NHL +1

Start: 2019-08-05End: 2030-03-31Target: 132Updated: 2026-04-01

Phase 3

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

RecruitingNCT06520163

The Affiliated People's Hospital of Ningbo UniversityHematopoietic Stem Cell Mobilization, Non-Hodgkin's Lymphoma

Start: 2024-08-01End: 2026-08-31Target: 99Updated: 2025-12-04

Related Papers

Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib

Blood2025-11-032 citations

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

Blood2025-11-03

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Blood2023-11-029 citations

Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma

Blood2023-11-02

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS

Hematological Oncology2023-06-018 citations

A phase 2, multicentre, open‐label trial (<scp>ACE‐LY</scp>‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

British Journal of Haematology2022-07-2128 citations

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Blood2021-11-053 citations

DOSE‐ADJUSTED EPOCH FOR LYMPHOMA‐ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A STONE TWO BIRDS

Hematological Oncology2019-06-01

Clinical Study Of Dose-Adjusted EPOCH Regimen For Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis: Preliminary Results Of An Ongoing Phase II Study

Blood2013-11-15